| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
51,330,000 |
| Market
Cap: |
11.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.2235 - $0.2235 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. Co.'s product candidate, FMX114, which is being evaluated for the potential treatment of mild-to-moderate atopic dermatitis. Co. is also in the preclinical stages of developing products containing Bromodomain and Extra-Terminal Domain (BET) inhibitor compounds. Co.'s initial BET inhibitor candidate in development is VYN201, an administered pan-BET inhibitor, which it is exploring in various immuno-inflammatory diseases, including skin diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
15,000 |
15,000 |
| Total Buy Value |
$0 |
$0 |
$43,800 |
$43,800 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Stuart Iain |
CHIEF SCIENTIFIC OFFICER |
|
2025-09-30 |
4 |
D |
$0.34 |
$822 |
D/D |
(2,453) |
117,687 |
|
- |
|
Zeronda Tyler |
CHIEF FINANCIAL OFFICER |
|
2025-09-30 |
4 |
D |
$0.34 |
$1,146 |
D/D |
(3,420) |
111,653 |
|
- |
|
Harsch Mutya |
CHIEF LEGAL OFFICER AND GC |
|
2025-09-30 |
4 |
D |
$0.34 |
$1,200 |
D/D |
(3,581) |
129,484 |
|
- |
|
Domzalski David |
PRESIDENT AND CEO |
|
2025-09-30 |
4 |
D |
$0.34 |
$4,246 |
D/D |
(12,676) |
428,892 |
|
- |
|
Stuart Iain |
CHIEF SCIENTIFIC OFFICER |
|
2025-06-30 |
4 |
D |
$1.65 |
$4,047 |
D/D |
(2,453) |
120,140 |
|
- |
|
Zeronda Tyler |
CHIEF FINANCIAL OFFICER |
|
2025-06-30 |
4 |
D |
$1.65 |
$5,643 |
D/D |
(3,420) |
115,073 |
|
- |
|
Domzalski David |
PRESIDENT AND CEO |
|
2025-06-30 |
4 |
D |
$1.65 |
$20,915 |
D/D |
(12,676) |
441,568 |
|
- |
|
Harsch Mutya |
CHIEF LEGAL OFFICER AND GC |
|
2025-06-30 |
4 |
D |
$1.65 |
$5,909 |
D/D |
(3,581) |
133,065 |
|
- |
|
Domzalski David |
PRESIDENT AND CEO |
|
2025-06-02 |
4 |
A |
$0.81 |
$7,032 |
D/D |
8,681 |
454,244 |
|
- |
|
Harsch Mutya |
CHIEF LEGAL OFFICER AND GC |
|
2025-06-02 |
4 |
A |
$0.81 |
$927 |
D/D |
1,145 |
136,646 |
|
- |
|
Stuart Iain |
CHIEF SCIENTIFIC OFFICER |
|
2025-03-31 |
4 |
D |
$1.58 |
$9,550 |
D/D |
(6,044) |
122,593 |
|
- |
|
Zeronda Tyler |
CHIEF FINANCIAL OFFICER |
|
2025-03-31 |
4 |
D |
$1.58 |
$13,270 |
D/D |
(8,399) |
118,493 |
|
- |
|
Domzalski David |
PRESIDENT AND CEO |
|
2025-03-31 |
4 |
D |
$1.58 |
$48,187 |
D/D |
(30,498) |
445,563 |
|
- |
|
Harsch Mutya |
CHIEF LEGAL OFFICER AND GC |
|
2025-03-31 |
4 |
D |
$1.58 |
$13,948 |
D/D |
(8,828) |
135,501 |
|
- |
|
Lepore Patrick G |
|
|
2025-01-15 |
4 |
B |
$2.92 |
$43,800 |
D/D |
15,000 |
51,472 |
0.01 |
- |
|
Zeronda Tyler |
CHIEF FINANCIAL OFFICER |
|
2024-12-31 |
4 |
D |
$3.35 |
$15,661 |
D/D |
(4,675) |
126,892 |
|
- |
|
Harsch Mutya |
CHIEF LEGAL OFFICER AND GC |
|
2024-12-31 |
4 |
D |
$3.35 |
$15,735 |
D/D |
(4,697) |
144,329 |
|
- |
|
Stuart Iain |
CHIEF SCIENTIFIC OFFICER |
|
2024-12-31 |
4 |
D |
$3.35 |
$16,271 |
D/D |
(4,857) |
128,637 |
|
- |
|
Domzalski David |
PRESIDENT AND CEO |
|
2024-12-31 |
4 |
D |
$3.35 |
$82,196 |
D/D |
(24,536) |
476,061 |
|
- |
|
Domzalski David |
PRESIDENT AND CEO |
|
2024-11-30 |
4 |
A |
$2.10 |
$8,192 |
D/D |
3,901 |
500,597 |
|
- |
|
Zeronda Tyler |
CHIEF FINANCIAL OFFICER |
|
2024-09-30 |
4 |
D |
$1.88 |
$158 |
D/D |
(84) |
131,567 |
|
- |
|
Harsch Mutya |
CHIEF LEGAL OFFICER AND GC |
|
2024-09-30 |
4 |
D |
$1.88 |
$197 |
D/D |
(105) |
149,026 |
|
- |
|
Stuart Iain |
CHIEF SCIENTIFIC OFFICER |
|
2024-09-30 |
4 |
D |
$1.88 |
$205 |
D/D |
(109) |
133,494 |
|
- |
|
Domzalski David |
PRESIDENT AND CEO |
|
2024-09-30 |
4 |
D |
$1.88 |
$1,288 |
D/D |
(685) |
496,696 |
|
- |
|
Harsch Mutya |
CHIEF LEGAL OFFICER AND GC |
|
2024-07-01 |
4 |
D |
$1.92 |
$275 |
D/D |
(143) |
149,131 |
|
- |
|
194 Records found
|
|
Page 1 of 8 |
|
|